First and only PARP inhibitor to improve invasive disease-free survival in patients
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
Dr. Reddy's acquired the Eton portfolio for an upfront payment of approximately $5 million in cash, plus contingent payments of up to $45 million.
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
U.S. FDA has issued Form 483 with six observations after an inspection of the company’s formulation manufacturing facility based out of Baddi
Sanjay Verma of Akums Drugs & Pharmaceuticals, Manu Gupta of Cadila Pharmaceuticals, Rahul Borse of RPG Life Sciences, Krishna Sai T of Biocon and Amit Saluja of NASSCOM are speakers
The company is strategically expanding its product portfolio with a pipeline of new products that will form a strong foundation for future growth.
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
Guindo will be responsible for leading the development and implementation of the company’s long-term strategy for the Human Health portfolio.
The US FDA had conducted an inspection of Alkem Laboratories Limited's manufacturing facility located at St. Louis, USA.
Subscribe To Our Newsletter & Stay Updated
